H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume
vTv Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital
U.S. STOCKS ON THE MOVE-Gold miners, Blackstone, PepsiCo
vTv jumps after FDA lifts clinical hold on diabetes therapy
vTv Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
Brief: vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
vTv Therapeutics falls after FDA places clinical hold on its diabetes study
Brief: VTv Therapeutics Got Into Second Amendment To License Agreement With Newsoara Biopharma Co
Brief: vTv Therapeutics Files For Mixed Shelf Offering Of $250 Mln
Brief: vTv Therapeutics Inc Says Nasdaq Notified Co That It Had Regained Compliance With Nasdaq Listing Rule On March 25
Brief: vTv Therapeutics Reduces Board Size To Seven Members
Brief: vTv Therapeutics Announces FDA Submission For First Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes
Brief: Vtv Therapeutics Announces $51 Million Private Placement
Brief: Vtv Therapeutics Gets Notice From Hangzhou Zhongmei Huadong Pharmaceutical Of Intent To Terminate License Agreement Dated Dec 21,2017
Brief: VTV Therapeutics Got Letter From Nasdaq Notifying It Is Not In Compliance With A Listing Rule
Brief: vTv Therapeutics Board Approved A Reverse Stock Split At A Ratio Of 1-For-40
Brief: Vtv Therapeutics Announces Sale Of Shares In Reneo Pharmaceuticals
Refinitiv Newscasts - Flash flooding hits Central Vietnam after heavy rains